Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
ChargePoint Holdings
AN
AnalystHighTarget
Consensus Narrative from 9 Analysts
Rising EV Adoption And Urbanization Will Spark Charging Network Expansion
Key Takeaways Strong Eaton partnership, next-gen hardware, and rapid EV adoption position ChargePoint for margin expansion and accelerated growth in untapped markets. Industry consolidation and integrated energy solutions enhance ChargePoint's pricing power and recurring revenue streams, supporting long-term profitability.
View narrative
US$51.62
FV
76.9% undervalued
intrinsic discount
30.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Diversified Healthcare Trust
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Aging Populations And Telehealth Trends Will Uplift Facilities
Key Takeaways Divesting underperforming assets and repositioning towards higher-quality properties is set to rapidly improve portfolio quality, margins, and long-term revenue growth. Strategic refinancing, favorable demographic trends, and robust institutional investor interest are expected to drive sustainable earnings upside and support long-term asset value appreciation.
View narrative
US$4.50
FV
25.1% undervalued
intrinsic discount
3.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Senseonics Holdings
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Telehealth Growth And Aging Populations Will Expand Glucose Monitoring
Key Takeaways Accelerating patient adoption, expanded provider networks, and new reimbursement pathways could drive revenue and margin growth well above current analyst expectations. Integration with connected diabetes technologies and long-term innovation plans position Senseonics to benefit from rising demand for advanced, user-friendly health wearables.
View narrative
US$2.00
FV
76.4% undervalued
intrinsic discount
88.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
EyePoint Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Aging Population And Diabetes Will Expand Ocular Therapies
Key Takeaways EyePoint's rapid clinical execution, manufacturing readiness, and global strategy position it for unmatched early market penetration and accelerated revenue growth ahead of competitors. Proprietary sustained-release technology, expanding indications, and demographic trends provide strong long-term revenue visibility, risk diversification, and enhanced attractiveness for strategic partnerships.
View narrative
US$59.30
FV
81.3% undervalued
intrinsic discount
67.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Fulgent Genetics
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Rapid Genomic Medicine Advances Will Reshape The Diagnostics Landscape
Key Takeaways Rapid expansion, proprietary technology, and early adoption in genomics position the company for sustained organic growth, first-mover advantage, and robust margin improvements. Automation, managed care expansion, and differentiated therapeutic pipelines enable superior scalability, recurring revenue stability, and significant upside in high-margin markets.
View narrative
US$30.00
FV
29.1% undervalued
intrinsic discount
10.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Ouster
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Autonomous Vehicles And AI Will Revolutionize Lidar Markets
Key Takeaways Ouster's advanced AI-driven software and expanding distributor network position it to outpace market expectations, capturing significant market share and driving substantial recurring revenue growth. Innovations in proprietary silicon and scalable platforms unlock new, high-margin markets beyond lidar, enabling sustained expansion with minimal additional operating costs.
View narrative
US$49.14
FV
29.3% undervalued
intrinsic discount
40.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
RxSight
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Entry Into European And Asian Markets Will Unlock New Opportunities
Key Takeaways Strategic realignment and international expansion target higher adoption, utilization, and new revenue streams, leveraging demographic trends and a growing emphasis on vision correction. Investments in innovation, education, and clinical support aim to broaden market share, enhance margins, and build long-term pricing power within the premium IOL segment.
View narrative
US$8.89
FV
5.2% undervalued
intrinsic discount
1.01%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
Updated
narrative
Ranpak Holdings
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
E-Commerce Surge And Sustainable Demand Will Redefine Packaging
Key Takeaways Structural cost reductions and a new global operating model are set to drive sustained margin expansion beyond what analysts currently anticipate. Leadership in sustainable packaging and automation positions Ranpak for long-term growth, increased market share, and enhanced cash flow potential.
View narrative
US$8.00
FV
47.0% undervalued
intrinsic discount
10.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Treace Medical Concepts
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Aging Population And Obesity Will Transform Foot Surgery
Key Takeaways Accelerated adoption of new systems and a highly skilled sales force could drive rapid revenue and earnings growth beyond the market's expectations. Expanding clinical evidence, demographic trends, and upcoming international launches are set to broaden the patient base and improve pricing power and margin resilience.
View narrative
US$12.00
FV
42.6% undervalued
intrinsic discount
10.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies